Drive against elephantiasis in 30 districts from March 4

- Rastriya Samachar Samiti, Kathmandu
10.5m people above two years of age to get anti-filarial drugs

Feb 7, 2017-The government is set to launch an anti-elephantiasis drug administration campaign in 30 districts from March 4. 

Under the three-day campaign to be coordinated by the Epidemiology and Disease Control Division (EDCD), the government plans to administer anti-filarial drugs to 10.5 million people above two years of age, according to Tulasi Adhikari, focal person for the EDCD. 

Children below two years of age, pregnant women, people with chronic diseases and new mothers in the first week of delivery will not be administered the drugs against the disease that is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea. 

There are 3 types of these thread-like filarial worms: Wuchereria bancrofti, which is responsible for 90 percent of the cases; Brugia malayi, which causes most of the remainder of the cases, and Brugia timori, which also causes the disease.

The anti-elephantiasis drug administration campaign is being run by the Ministry of Health since 2003. 

The campaign will be launched in Panchthar, Ilam, Jhapa, Morang, Sunsari, Dhankuta, Bhojpur, Tehrathum, Udaypur, Lalitpur, Lamjung, Parbat, Myagdi, Baglung, Kapilvastu, Dang, Banke, Bardiya, Surkhet, Dailekh, Jajarkot, Kailali, Kanchanpur, Dadeldhura, Doti, Accham, Bajura, Bajhang, Baitadi and Darchula. 

Elephantiasis, as it is commonly known, is also called lymphatic filariasis and is a neglected tropical disease and transmitted to humans through mosquitoes. 

Infection is usually acquired in childhood causing hidden damage to the lymphatic system.

Elephantiasis infection involves asymptomatic, acute, and chronic 


The majority of infections are asymptomatic, showing no external signs of infection. These asymptomatic infections still cause damage to the lymphatic system and the kidneys, and alter the body’s immune system.

Published: 07-02-2017 08:29

User's Feedback

Click here for your comments

Comment via Facebook

Don't have facebook account? Use this form to comment